Status:
COMPLETED
Fluoxetine to Reduce Intubation and Death After COVID19 Infection
Lead Sponsor:
University of Toledo Health Science Campus
Conditions:
COVID-19
Cytokine Storm
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This project will test the efficacy of fluoxetine to prevent serious consequences of COVID-19 infection, especially death. Becoming sick with COVID-19 virus or any other serious respiratory condition ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients aged 18 and above, able to give informed consent or with legally authorized representative
- COVID-19 test positive or presumptive positive awaiting COVID testing or results by following criteria: fever, cough and shortness of breath or presumptive positive by one of these 3 criteria (fever, cough or shortness of breath) and known exposure to COVID-19 positive individual in past 2 weeks
- Overall Study Exclusion Criteria :
- Unable to give informed consent and no legal representativ
- Prisoner/ institutionalized patient
- Under age 18
- Exclusion from Fluoxetine Arm:
- Active bleeding requiring blood products
- Bipolar disorder not on mood stabilizing medication\*
- Known allergy or hypersensitivity to fluoxetine
- Currently taking the following medications : MAO I, pimozide, thioridine
- Currently taking hydroxychloroquine
- Pregnant or breastfeeding
- For hospitalized patients : QTc greater than 500 ms
- \*Hospitalized patient may be on hydroxychloroquine if QTc\<500 and the primary attending approves
- Exclusion from Blood Sample Provision:
- Pregnant
- Self-report of under 110 pounds
Exclusion
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04377308
Start Date
May 1 2020
End Date
April 30 2021
Last Update
June 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Toledo
Toledo, Ohio, United States, 43614